Skip to content

Study · Not a test of the peptide alone · 2025

10 results

Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.

Seetharaman S, Cengiz E

Journal of diabetes science and technology21 Dec 2024Cited by 7 (Europe PMC)

PMID39707844 (opens in a new tab)PMCIDPMC11662345 (opens in a new tab)DOI10.1177/19322968241305641 (opens in a new tab)PepBankPUB-39707844
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

BackgroundType 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to lifelong insulin dependence. Despite advancements in insulin therapies and glucose monitoring, maintaining optimal blood glucose control remains challenging with common issues like weight gain and glucose variability. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), approved for type 2 diabetes and obesity, are being explored off-label for T1D.Case reportThis case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.DiscussionMost patients had obesity, consistent with typical indication for use in AYA. Common gastrointestinal side effects improved with dose titration, but careful monitoring is needed for persistent symptoms. One patient developed an eating disorder, underscoring the need for vigilance. Insurance and medication shortage issues impacted treatment continuity, highlighting the need for better support. Glycemic parameters improved in most patients, with weight reduction in several patients with obesity, and no reported diabetic ketoacidosis.ConclusionsGLP-1 RAs can be a beneficial adjunct therapy in T1D, improving glycemic control, reducing insulin needs, and supporting weight management, while potentially preventing long-term cardiovascular and renal complications.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In adolescents and young adults with type 1 diabetes, glycemic parameters improved in most patients given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled).

    In plain wordsIn young people with type 1 diabetes, blood sugar measures improved in most patients on GLP-1 drugs, mainly semaglutide and tirzepatide, taken together.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycemic parameters
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycemic parameters improved in most patients
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In adolescents and young adults with type 1 diabetes, glycemic parameters improved in most patients given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled).

    In plain wordsIn young people with type 1 diabetes, blood sugar measures improved in most patients on GLP-1 drugs, mainly semaglutide and tirzepatide, taken together.

    Peptide
    Tirzepatide
    Outcome
    DecreaseGlycemic parameters
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glycemic parameters improved in most patients
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In adolescents and young adults with type 1 diabetes and obesity, several patients had weight reduction on adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled).

    In plain wordsIn young people with type 1 diabetes and obesity, several lost weight on GLP-1 drugs, mainly semaglutide and tirzepatide, taken together.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction in patients with obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    with weight reduction in several patients with obesity
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In adolescents and young adults with type 1 diabetes and obesity, several patients had weight reduction on adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled).

    In plain wordsIn young people with type 1 diabetes and obesity, several lost weight on GLP-1 drugs, mainly semaglutide and tirzepatide, taken together.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight reduction in patients with obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    with weight reduction in several patients with obesity
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), no diabetic ketoacidosis was reported.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, no diabetic ketoacidosis was reported.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetic ketoacidosis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    no reported diabetic ketoacidosis.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), no diabetic ketoacidosis was reported.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, no diabetic ketoacidosis was reported.

    Peptide
    Tirzepatide
    Outcome
    No significant changeDiabetic ketoacidosis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    no reported diabetic ketoacidosis.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 07HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), common gastrointestinal side effects improved with dose titration.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, common stomach and gut side effects eased with slow dose increases.

    Peptide
    Semaglutide
    Outcome
    DecreaseGastrointestinal side effects with dose titration
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Common gastrointestinal side effects improved with dose titration, but careful monitoring is needed for persistent symptoms.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), common gastrointestinal side effects improved with dose titration.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, common stomach and gut side effects eased with slow dose increases.

    Peptide
    Tirzepatide
    Outcome
    DecreaseGastrointestinal side effects with dose titration
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Common gastrointestinal side effects improved with dose titration, but careful monitoring is needed for persistent symptoms.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  9. 09HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), one patient developed an eating disorder.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, one patient developed an eating disorder.

    Peptide
    Semaglutide
    Outcome
    IncreaseEating disorder
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    One patient developed an eating disorder, underscoring the need for vigilance.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  10. 10HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome

    In adolescents and young adults with type 1 diabetes given adjunct GLP-1 receptor agonists (mainly semaglutide and tirzepatide, pooled), one patient developed an eating disorder.

    In plain wordsIn young people with type 1 diabetes on GLP-1 drugs, mainly semaglutide and tirzepatide, one patient developed an eating disorder.

    Peptide
    Tirzepatide
    Outcome
    IncreaseEating disorder
    Study

    n: not reported in source

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    One patient developed an eating disorder, underscoring the need for vigilance.
    1 context sentence
    Summary · context
    This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.